Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia

Levin-Epstein, Rebecca; Oliai, Caspian; Schiller, Gary J.

doi:10.1007/s11864-018-0577-2

Cited by 22 publications

(18 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Traditionally, allo‐HSCT in the elderly has a higher TRM because of the patient's frequent comorbidities and poor performance status. Reports from main transplant centers for older patients have shown 2‐year TRM rates ranging from 7% to 35% 2,7,24‐26 . Some studied reported that myeloablative conditioning regimen (MAC) was associated with higher TRM rates compared to those who underwent nonmyeloablative conditioning (NMAC) or reduced intensity (RIC) conditioning regimen 27‐30 .…”

Section: Discussionmentioning

confidence: 99%

“…With technical advance in allo‐HSCT, it has been broadened the application of older population, and its upper age limit has risen from 40 to 45 to 70 and to 75 years over the past four decades 2,3 . A growing number of studies have demonstrated that allo‐HSCT results in improvement of outcomes and is not a contraindication for older AML and MDS 4‐8 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single‐center retrospective study

Huang

Zhang

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a potentially curative therapeutic option for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Increasing data suggest that haploidentical donor (HID) transplantation achieve comparable outcomes with HLA‐matched sibling donor (MSD) in adult AML/MDS. This retrospective study compared the outcomes of AML or MDS patients age ≥50 years underwent HID and MSD transplantation. One hundred and fifty‐six patients were enrolled in this study, including 75 HID and 81 MSD transplantation. The 100‐day cumulative incidence of II‐IV° acute graft‐versus‐host disease (GVHD) was 33.3 ± 5.4% vs 22.2 ± 4.6%, respectively, in HID and MSD groups (P = .066), and III‐IV° acute GVHD was not significantly different between two groups (5.3%±2.6% vs 6.2%±2.7%, respectively, P = .823). The 2‐year cumulative incidence of limited and extensive chronic GVHD was not statistically different in HID and MSD groups (20.9 ± 5.5% vs 18.9 ± 4.8% and 13.0 ± 4.7% vs 19.7 ± 5.0%, P = .889 and P = .269, respectively). The 2‐year cumulative incidences of relapse (27.0 ± 5.6% vs 22.7 ± 5.1%, P = .509), 2‐year overall survival (63.0 ± 5.8% vs 66.7 ± 5.4%, P = .454), 2‐year transplant‐related mortality (17.2 ± 4.6% vs 17.4 ± 4.4%, P = .847), 2‐year progression‐free survival (59.3 ± 5.8% vs 64.5 ± 5.4%, P = .437), 2‐year GVHD‐free relapse‐free survival (42.6 ± 5.9% vs 40.9 ± 5.6%, P = .964) were not significantly different in the two groups. The present data showed equivalent outcomes in AML or MDS patients age ≥50 years underwent HID and MSD transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single‐center retrospective study

Huang

Zhang

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Traditionally, allo-HSCT in the elderly has had a higher risk of TRM because of the patients' frequent comorbidities and poor performance status. Reports from main transplant centers for older patients have shown 2-year TRM rates ranging from 7% to 35% (2,7,(17)(18)(19). Some studies have reported that a myeloablative conditioning regimen (MAC) is associated with higher TRM rates than a nonmyeloablative conditioning (NMAC) or a reduced-intensity (RIC) conditioning regimen (20)(21)(22)(23).…”

Section: Discussionmentioning

confidence: 99%

Haploidentical Related Donor versus Matched Sibling Donor Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome Aged Over 50 Years: A Single-Center Retrospective Study.

Huang

Zhang

et al. 2019

Preprint

View full text Add to dashboard Cite

BACKGROUND Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Increasing data supports the utility of haploidentical related donor (HID) HSCT in fit older patients and resulting in improvement of outcomes. This study compared the outcomes of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients age ≥50 years underwent haploidentical related donor (HID) or matched sibling donor (MSD) allogeneic hematopoietic stem cell transplantation (allo-HSCT).METHODS We retrospectively studied 38 patients with AML/MDS aged ≥50 years who underwent HID transplantation and compared their outcomes with 55 similarly aged patients who underwent MSD transplantation.RESULTS The 100-day cumulative incidence of II-IV° acute graft-versus-host disease (GVHD) were 34.2 ± 7.7% and 23.6 ± 5.7%, respectively, in HID and MSD groups (P = 0.189), and III-IV° acute GVHD were similar between two groups (5.3% and 7.3%, respectively, P=0.700). The 2-year cumulative incidence of limited and extensive chronic GVHD was not statistically different in HID and MSD groups(22.8 ± 10.8% vs. 18.2 ± 6.0% and 18.3 ± 10.4% vs. 22.1 ± 6.8%, P = 0.890 and P=0.424, respectively). The 2-year cumulative incidences of relapse (29.5±10.3% and 20.7 ±6.1%, P=0.458), 2-year overall survival (58.5±9.7% and 67.9±6.8%, P=0.373), 2-year transplant-related mortality (17.3±6.4% and 15.0±5.3%, P=0.717), 2-year progression free survival (56.8±9.7% and 64.6±7.4%, P=0.312) were similar in the two groups.CONCLUSION The present data showed similar outcomes in patients aged 50 years and older underwent HID compared to MSD at our institution.

show abstract

“…Traditionally, allo-HSCT in the elderly has a higher TRM because of the patient's frequent comorbidities and poor performance status. Reports from main transplant centers for older patients have shown 2-year TRM rates ranging from 7% to 35% (2,7,(17)(18)(19). Some studied reported that myeloablative conditioning regimen (MAC) was associated with higher TRM rates compared to those who underwent nonmyeloablative conditioning (NMAC) or reduced-intensity (RIC) conditioning regimen (20)(21)(22)(23).…”

Section: Discussionmentioning

confidence: 99%

“…With technical advance in allo-HSCT, it has been broadened the application of older population, and its upper age limit has risen from 40 to 45 to 70 and to 75 years over the past 4 decades(2, 3). A growing number of studies has demonstrated that allo-HSCT results in improvement of outcomes and is not a contraindication for older AML and MDS (4)(5)(6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

Haploidentical Related Donor versus Matched Sibling Donor Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome Aged Over 50 Years: A Single-Center Retrospective Study.

Huang¹,

Huang²,

Zhang³

et al. 2019

Preprint

View full text Add to dashboard Cite

BACKGROUND Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Increasing data supports the utility of haploidentical related donor (HID) HSCT in fit older patients and resulting in improvement of outcomes. This study compared the outcomes of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients age ≥50 years underwent haploidentical related donor (HID) or matched sibling donor (MSD) allogeneic hematopoietic stem cell transplantation (allo-HSCT).METHODS We provided HID transplantation to 38 patients of AML/MDS age ≥50 years and compared their outcomes with 55 patients of the same ages who underwent matched sibling donor (MSD) transplantation.RESULTS The 100-day cumulative incidence of II-IV° acute graft-versus-host disease (GVHD) were 34.2 ± 7.7% and 23.6 ± 5.7%, respectively, in HID and MSD groups (P = 0.189), and III-IV° acute GVHD were similar between two groups (5.3% and 7.3%, respectively, P=0.700). The 2-year cumulative incidence of limited and extensive chronic GVHD was not statistically different in HID and MSD groups(22.8 ± 10.8% vs. 18.2 ± 6.0% and 18.3 ± 10.4% vs. 22.1 ± 6.8%, P = 0.890 and P=0.424, respectively). The 2-year cumulative incidences of relapse (29.5±10.3% and 20.7 ±6.1%, P=0.458), 2-year overall survival (58.5±9.7% and 67.9±6.8%, P=0.373), 2-year transplant-related mortality (17.3±6.4% and 15.0±5.3%, P=0.717), 2-year progression free survival (56.8±9.7% and 64.6±7.4%, P=0.312) were similar in the two groups.CONCLUSION We conclude that HID allo-SCT is feasible and safe for elderly AML/MDS patients.

show abstract

Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia

Cited by 22 publications

References 59 publications

Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single‐center retrospective study

Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single‐center retrospective study

Haploidentical Related Donor versus Matched Sibling Donor Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome Aged Over 50 Years: A Single-Center Retrospective Study.

Haploidentical Related Donor versus Matched Sibling Donor Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome Aged Over 50 Years: A Single-Center Retrospective Study.

Contact Info

Product

Resources

About